Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

12 results about "AN - Anorexia nervosa" patented technology

Anorexia nervosa, often referred to simply as anorexia, is an eating disorder characterized by low weight, fear of gaining weight, and a strong desire to be thin, resulting in food restriction.

Treating or preventing anorexia nervosa via precision targeting of neuronal circuit

PendingUS20260183549A1Active agentAnorectic
Methods of treating one or more eating disorders including anorexia nervosa, bulimia, and related clinical syndromes in a subject in need thereof are described. In some cases, electric stimulation and / or one or more active agents are administered to a subject in need thereof to reduce or inhibit the activity of CeA PKC-δ neurons and ovBNST PKC-δ neurons in the brain of the subject. Preferably, the disclosed methods are effective to increase or excite the activity of the brain regions downstream of CeA PKC-δ neurons and ovBNST PKC-δ neurons including medial part of CeA and ventral lateral part of BNST.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Multi-modal data-based anorexia risk prediction system

The invention relates to the technical field of anorexia risk prediction, and discloses an anorexia risk prediction system based on multi-modal data, which comprises a multi-dimensional monitoring module and an intelligent evaluation module. According to the system, health management data and daily life management data of all individuals are obtained through a multi-dimensional monitoring module and are classified to form a data set, and an intelligent evaluation module evaluates the actual energy demand required by the individuals for maintaining the current body weight, generates basic energy consumption, evaluates the individual physical activity level coefficient, generates an energy intake gap, and obtains the health management data and the daily life management data. Metabolic characteristics of different ages, genders and groups are fully considered, the multi-dimensional assessment precision is high, the intelligent assessment module sets a fixed monitoring period, dynamically tracks the change trend of health key indexes, accurately quantifies and assesses the health injury degree of an individual caused by anorexia behaviors, generates injury indexes, quantifies risk levels, and improves the assessment accuracy. Intendencies of individuals to different anorexia subtypes are distinguished, corresponding early warning signals and feeding suggestions are output, and grading early warning screening efficiency is high.
Owner:中国人民解放军总医院第八医学中心

Diagnosing and monitoring therapeutic effects of clearance activity and emotional behavior in eating disorders

PendingCN120712617AMedical data miningMedical automated diagnosisData setPhysiological markers
Methods and systems are provided for taking physiological marker measurements for a patient suffering from an eating disorder (e.g., anorexia nervosa, greedy nervosa, violent eating, heterophagia syndrome, ruminant disorder, or truncated food intake). Mathematical analysis of physiological marker measurements is used to create a unique personal prediction model and a unique personal data set for an individual patient, including personal prediction of the entire stage of a disorder (violence, nausea and clearance). The unique personal data set is used to diagnose and monitor specific issues of individual patients associated with eating disorders, determine the severity of the disorders, provide intraday alarms to assist in sustained disorder management or recommend treatment of specific issues of individual patients associated with these eating disorders, or predicts the outcome of a treatment for a particular problem of individual patients associated with these eating disorders.
Owner:B·K·勒维

Diagnosis and monitoring treatment effectiveness for cleansing activities and purging behaviors in eating disorders

PCT designated stage expiredWO2025153911A1Medical data miningMedical automated diagnosisRumination DisorderDisease
A method and a system are provided for taking physiological markers measurements of patients who have an eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder, pica syndrome, rumination disorder or refrained food consumption). Mathematical analysis of the physiological markers measurements is used to create a unique personal prediction model and data set for an individual patient, including personal predictions for the entire stages of the disorder (binge, nausea and cleansing). The unique personal data set is used to diagnose and monitor a particular problem of the individual patient associated with the eating disorder, determine the disorder's severity, provide intraday alerts to assist in the ongoing disorder management or to recommend a treatment for a particular problem of the individual patient associated with these eating disorders, or to predict an outcome of a treatment for a particular problem of the individual patient associated with these eating disorders.
Owner:LEVY BIRKAT KLIMSHTEIN

Methods for treating anorexia nervosa and related conditions by administering a leptin receptor agonist

ActiveUS12651658B2Peptide/protein ingredientsDrug and medicationsGaining weightMetreleptin
The invention concerns methods for treating unwanted body weight loss, and / or medically undesired body weight loss, or eating disorders (such as anorexia nervosa), by administration of a leptin receptor agonist, such as metreleptin. The invention also relates to methods for increasing body weight in a subject in need of the treatment.
Owner:UNIV DUISBURG ESSEN

Methods of treatment for anorexia nervosa

A method is provided for treating neurogenic anorexia nervosa in a subject in need thereof, using a magnetic resonance guided focused ultrasound treatment system. The method comprises applying high-intensity focused ultrasound energy to multiple treatment target points on the bilateral anterior limbs of the left and right internal capsules of the subject to regulate the bilateral anterior limbs of the subject; and inducing normalization of weight in the subject.
Owner:SHANGHAI HAOYISHENG ENTERPRISE MANAGEMENT PARTNERSHIP (LLP)

Application of Prazosin in preparation of medicine for treating anorexia nervosa

The invention provides an innovative AN drug treatment strategy, and based on a prazosin targeted LC-NE neural circuit, the weight is increased and the AN symptom is improved by reducing LC-NE neuron over-excitation, restoring appetite and improving the anxiety state. The application is characterized in that: different from the traditional antidepressant or antipsychotic drug, the pazosin can directly regulate and control the feeding loop. The safety is high, clinical use experience exists, and indications can be directly expanded. Individual treatment schemes are provided and can be independently used or combined for treatment, and the curative effect is improved. The application is expected to provide a new thought and a new drug choice for AN treatment, and promote the research of the NE system in eating disorders.
Owner:SHANGHAI SONGJIANG DISTRICT CENTRAL HOSPITAL

Methods of treatment for anorexia nervosa

A method is provided for treating neurogenic anorexia nervosa in a subject in need thereof, using a magnetic resonance guided focused ultrasound treatment system. The method comprises applying high-intensity focused ultrasound energy to multiple treatment target points on the bilateral anterior limbs of the left and right internal capsules of the subject to regulate the bilateral anterior limbs of the subject; and inducing normalization of weight in the subject.
Owner:SHANGHAI HAOYISHENG ENTERPRISE MANAGEMENT PARTNERSHIP (LLP)

SiRNA for inhibiting melanocortin receptor 4 (MC4R) gene expression, medicine and application thereof

The invention provides siRNA for inhibiting melanocortin receptor 4 (MC4R) gene expression in human cells, a polypeptide oligonucleotide conjugate and application of the polypeptide oligonucleotide conjugate, the siRNA comprises a positive-sense strand and a corresponding antisense strand, and the nucleotide composition of the siRNA is each group of corresponding positive-sense strand and corresponding complementary antisense strand in a table 1, or a sequence having a difference of no more than 3 nucleotides from its sense strand or antisense strand. According to the invention, a plurality of siRNAs which can be used for inhibiting MC4R expression are screened, and on the basis, proper modification is carried out to improve the silence capability of a target. And moreover, a unique delivery system is adopted to enable the siRNA to be delivered into the brain to play a role, so that the siRNA is expected to be applied to energy metabolism disorder diseases, such as cachexia, sarcopenia, emaciation syndrome and anorexia nervosa, which are clinically related to MC4R target spots, and other consumptive diseases caused by chronic inflammation, cancer and immune disorder, such as cachexia, sarcopenia, emaciation syndrome and anorexia nervosa.
Owner:GUANGZHOU BEBETTER MEDICINE TECH CO LTD